LISAvienna: December newsletter available online

Name: _pk_id Used for : Is used to store an unique ID for each user Duration : 13 Months
Name: &nbsp;_pk_ses, _pk_cvar, _pkhsr Used for :&nbsp;Session cookies that store temporary data Duration :&nbsp;30 minutes
Name: mtm_consent Used for : Stores cookie preferences Duration : 30 years

Today’s edition feature headlines from Novid20, invIOs, Valneva, ViruSure, Xund, MedUni Vienna, Solnatide Projekt, Evercyte, myReha, Ares Genetics, famado, Solgenium, Sofy, contextflow, Scarletred, cogvis, Cebina, BlueSky Immunotherapies, Semperit, HeartBeat.bio, IMBA; Origimm and Lifebrain.

In addition, we update you on the trade shows and partnering conferences we plan to attend in 2022, media articles, events and funding deadlines.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.

LISAvienna: December newsletter available online

Uni Vienna: Giant Viruses Infect Deadly Parasite

BMAW: Kocher: Österreich auf dem Weg zur höchsten Forschungsquote in der EU

Österreich investiert 2024 so viel wie nie zuvor in Forschung: Forschungsquote steigt auf 3,34%